Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SciSparc Ltd. ( (SPRC) ) has shared an update.
On August 7, 2025, SciSparc Ltd. announced a significant advancement in its collaboration with Clearmind Medicine Inc., resulting in the publication of an international patent application for a novel combination therapy targeting obesity and high blood sugar. The therapy combines Clearmind’s 5-methoxy-2-aminoindane (MEAI) with SciSparc’s Palmitoylethanolamide (PEA) to address metabolic syndrome, a condition affecting up to one-third of U.S. adults. This milestone underscores the collaboration’s focus on innovative therapies for mental health disorders and metabolic conditions, potentially enhancing SciSparc’s industry positioning and offering new solutions for widespread health challenges.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases. The company leverages cannabinoid pharmaceuticals and is engaged in drug development programs for conditions such as Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus. Additionally, SciSparc has a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 24,762
Technical Sentiment Signal: Sell
Current Market Cap: $2.97M
For an in-depth examination of SPRC stock, go to TipRanks’ Overview page.